Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy

NCT01857232 is registered in ClinicalTrials.gov with Acacia Pharma Ltd as lead sponsor.

NCT NCT01857232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01857232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy
Lead sponsor
Acacia Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
February 28, 2015
Enrollment
342 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cinv